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Abstract
Background: Axenfeld-Rieger syndrome (ARS) is associated with mutations in the PITX2 gene
that encodes a homeobox transcription factor. Several intronic PITX2  mutations have been
reported in Axenfeld-Rieger patients but their effects on gene expression have not been tested.
Methods: We present two new families with recurrent PITX2 intronic mutations and use PITX2c
minigenes and transfected cells to address the hypothesis that intronic mutations effect RNA
splicing. Three PITX2 mutations have been analyzed: a G>T mutation within the AG 3' splice site
(ss) junction associated with exon 4 (IVS4-1G>T), a G>C mutation at position +5 of the 5' (ss) of
exon 4 (IVS4+5G>C), and a previously reported A>G substitution at position -11 of 3'ss of exon
5 (IVS5-11A>G).
Results: Mutation IVS4+5G>C showed 71% retention of the intron between exons 4 and 5, and
poorly expressed protein. Wild-type protein levels were proportionally expressed from correctly
spliced mRNA. The G>T mutation within the exon 4 AG 3'ss junction shifted splicing exclusively
to a new AG and resulted in a severely truncated, poorly expressed protein. Finally, the A>G
substitution at position -11 of the 3'ss of exon 5 shifted splicing exclusively to a newly created
upstream AG and resulted in generation of a protein with a truncated homeodomain.
Conclusion: This is the first direct evidence to support aberrant RNA splicing as the mechanism
underlying the disorder in some patients and suggests that the magnitude of the splicing defect may
contribute to the variability of ARS phenotypes, in support of a gene dosage model of Axenfeld-
Rieger syndrome.
Background
Axenfeld-Rieger syndrome (ARS) is an autosomal-domi-
nant disorder with complete penetrance but variable
expressivity, and is one of the developmental conditions
of Axenfeld-Rieger spectrum. The spectrum is defined on
the basis of specific eye anomalies that include prominent
annular white line near the limbus at the level of
Descemet membrane (posterior embryotoxon), hypo-
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plastic iris, irido-corneal adhesions and glaucoma [1-5].
Diagnosis of ARS is established when the above-described
ocular features are accompanied by other systemic abnor-
malities, most commonly craniofacial, dental and umbil-
ical defects. Craniofacial anomalies usually consist of
maxillary hypoplasia, thin lip and dysplastic ears. Dental
defects vary from small teeth to complete anodontia with
missing lateral mandibular incisors being the most com-
mon feature. Umbilical anomalies may range from iso-
lated redundant skin at the site of the umbilicus to severe
hernias or omphalocele. Among other associated anoma-
lies, pituitary and cardiac defects, hearing loss, hydroceph-
alus and hypospadius have been reported [6-8].
Axenfeld-Rieger spectrum is a heterogeneous condition.
Mutations in PITX2  (4q25),  FOXC1  (6p25),  PAX6
(11p12), and a yet to be identified gene at 13q14 have
been shown to result in Axenfeld-Rieger isolated eye
anomalies as well as the complete syndrome [9-15]. Ocu-
lar manifestations of PITX2 mutations show broad varia-
bility, both between and within families. To date, the
reported phenotypes include Rieger and Axenfeld anom-
aly, iris hypoplasia, iridogoniodysgenesis, Peters' anom-
aly, aniridia and ring dermoid of cornea [9,16-27]. The
PITX2  gene encodes a homeodomain-containing tran-
scription factor and spans about 20 kb of genomic
sequence and includes six exons that encode four alterna-
tive transcripts that arise by alternative splicing and the
differential use of three promoters [28]. Although gain-of-
function mutations have been reported [19,29], a defi-
ciency in normal PITX2 protein (haploinsufficiency) is
suggested to be the major mechanism of ARS. This is sup-
ported by the presence of large deletions that include
PITX2 in some Axenfeld-Rieger patients and functional
studies of proteins derived from mutant alleles. A correla-
tion between the dosage of normal PITX2 protein and the
severity of the phenotype was noted [19,20,30,31]. Most
of the human PITX2 mutations described thus far affect
regions encoding the homeodomain- or C-terminal
domains, although a few intronic mutations have been
reported (see references above).
Pre-mRNA splicing is the process whereby introns are
removed and exons are joined to produce mature mRNA.
RNA splicing is facilitated by a large macromolecular
machine, the spliceosome, which recognizes conserved
sequences at intron/exon borders, including the 5' and 3'
splice sites and branchpoint sequence [32]. In a few
instances,  PITX2  mutations have been identified in
introns either at or in close proximity to splice sites (ss)
associated with the last two exons. These observations
suggest that splicing defects might explain the syndrome
in these individuals. To date, only coding region muta-
tions in PITX2 have been investigated. Here, we report the
identification of two new human families with intronic
PITX2 mutations and present an analysis of the effects of
intronic mutations on PITX2  mRNA splicing. The data
suggest that aberrant RNA splicing underlies the disorder
in six families and that the degree of aberrant splicing may
contribute to the variability of Axenfeld-Rieger syndrome
phenotypes.
Methods
Identification of PITX2 mutations
DNA samples obtained from new patients with ARS and
anomaly were screened for PITX2 gene mutations in exons
and at least 100-bp into adjacent intron regions as previ-
ously described [9]. DNA was isolated from blood spots
using the QIAGEN QIamp® DNA mini kit following the
dried blood spot protocol. PCR was conducted in a Gene-
Amp® PCR system 9700 in 30 μl reactions containing 1.5
mmol/l Mg 2+, 40–100 ng DNA, Biolase Reaction Buffer
(Bioline), 0.25 mM each dNTP, 1.5 units Biolase DNA
polymerase (Bioline) and 0.2 μM of each oligodeoxynu-
cleotide primer. Cycling profile was one cycle of 94°C for
five minutes, 30 cycles of 94°C for 45 seconds, 56°C for
45 seconds, and 72°C for 45 seconds, and one cycle of
72°C for ten minutes. Products were either purified using
Millipore MultiScreen® Separations System or sequenced
directly. Products were sequenced bidirectionally with an
ABI Prism®  3700 DNA sequencer using ABI Prism®
BigDye™ Terminator Cycle Sequencing Ready Reaction
Kits. The 20 μl reactions contained 5% DMSO, 1 μl of PCR
product DNA, and 0.32 μM oligodeoxynucleotide primer.
Cycling profile was conducted in a GeneAmp® PCR System
9700. Cycling profile was one cycle of 96°C for 30 sec-
onds, 35 cycles of 96°C for ten seconds, 50°C for 5 sec-
onds and 60°C for four minutes. Extension products were
purified using Agencourt CleanSEQ® Reaction Clean up.
PCR products were then sent to Agencourt, Inc to be
sequenced. Sequences were manually examined for muta-
tions and confirmed by additional independent amplifi-
cation and sequencing.
PITX2 DNA constructs
A primer positioned at g.16944 of the PITX2  genomic
sequence (GenBank accession number AF238048) and a
downstream primer at g.17393 were used to PCR-amplify
a 473 bp fragment that included part of exon 1b and the
downstream intron using human genomic DNA as a PCR
template; EcoRI and BamHI sites were appended to the 5'
and 3' ends, respectively. Primers are listed in Table 1. A
653 bp fragment containing exon 4 and surrounding
intron was amplified using an upstream primer at posi-
tion g.17812 (with a 5' BamHI site appended) and a
downstream primer at g.18439 containing a 3' KpnI site.
A 713 bp fragment containing a portion of exon 5 and the
upstream intron was generated using an upstream primer
positioned at g.20001 and a downstream primer at
g.21147; 5' KpnI and 3' HindIII sites were added to prim-BMC Medical Genetics 2006, 7:59 http://www.biomedcentral.com/1471-2350/7/59
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ers. Cycling profile was one cycle of 94°C for 45 s, 30
cycles at 94°C for 45 s, 60°C (55°C for exon 1b) for 45 s,
and 72°C for 45 s, and one cycle of 72°C for 10 min. Frag-
ments were inserted individually into pGEM-3Z
(Promega) using the same restriction sites, and plasmids
were sequenced using an ABI PRISM BigDye Terminator
v3.1 cycle sequencing kit (Applied Biosystems). Using the
appended restriction sites, exon/intron fragments were
excised from pGEM-3Z and shuttled sequentially into the
same sites of pcDNA3.1/myc-His(-)A (Invitrogen) to cre-
ate the PITX2c minigene (Figure 2B). Mutant minigenes
were constructed by overlap PCR using the above pGEM-
3Z constructs as template [33]. Sense and antisense prim-
ers containing the desired mutations were used with the
appropriate outside primer for PCR to synthesize half-
substrates. Mutant exon fragments were inserted into
pGEM-3Z and mutations were verified by DNA sequenc-
ing. The mutant fragments were then used to replace the
WT fragment in the minigene construct as described
above. N-terminal FLAG-epitope tagged minigenes were
constructed by excising the entire minigene from the
pcDNA constructs using SalI and a partial EcoRI digestion,
and shuttling the fragments into the same sites of p3X-
FLAG CMV 7.1 (Sigma).
Transfection and RNA analysis
HEK293 and HeLa cells were grown in minimal essential
growth medium supplemented with 10% fetal calf serum.
Human cornea stromal cells were grown in Dulbecco's
modified Eagle medium supplemented with 10% fetal
calf serum. Cells were grown to about 60% confluence in
6 cm dishes (HEK293 and HeLa) or 6 well plates (cornea
stromal cells) and transfected with 2 μg of minigene DNA
and 0.5 μg GFP using the calcium phosphate method
(Amersham Biosciences) for HEK293 and HeLa cells, or
Lipofectamine (Invitrogen) for cornea stromal cells. Total
RNA was harvested 48 h later using the Qiagen RNeasy kit.
For RT-PCR, reverse transcription was performed on 1 μg
of total RNA using oligo dT in a volume of 25 μl. For PCR,
2.5 μl of the reverse transcription mixture was used in a 25
μl PCR reaction using the T7 primer to pcDNA3.1/myc-
His(-)A vector and to exon 5 (for minigene mRNA) or to
exon 1b and exon 5 (for endogenous plus minigene
mRNA), and primers to GFP or cellular GAPDH. Cycling
conditions were one cycle of 94°C for 45 seconds, 30
cycles of 94°C for 45 seconds, 60°C for 45 seconds, and
72°C for 45 seconds, and one cycle of 72°C for 45 sec-
onds. To evaluate the accuracy of splicing of WT and
mutant mRNA, RT-PCR products were cloned and
sequenced. RT-PCR products were blunted with Klenow
fragment and then digested with EcoRI, which cuts at a
site located upstream of exon 1b. The products were
inserted into the EcoRI and SmaI sites of pGEM-3Z and
individual clones were sequenced. To assess minigene
splicing by RNase protection assay, a 700 bp riboprobe
was made by in vitro transcription using T7 polymerase
and HindIII-linearized pGEM-3Z containing the exon/
intron 4 fragment. This includes 264 nt and 183 nts of
upstream and downstream intron, respectively, that flank
the 206 nt exon 4. A 371 nt GFP riboprobe was made
using SP6 polymerase and EcoRI-linearized pGEM-3Z
containing a GFP fragment. RNase protection assays were
carried out as described previously [34] using 2.5 μg RNA.
Correct splicing generates a ~206 nt protected band and
Table 1: Oligonucleotides used in this study
Name Sequence* Purpose
Ex-1b-f GCGAATTCCAGTAGCCAAGGACTAGTAG Forward and reverse primers to make exon 1b fragment
Int-1b-r GCGGATCCAGAATTGCTCGCGCCCTTAG
Int-1b-f GCGGATCCAGTGAATGTGCCGCTGCAGT Forward and reverse primers to make exon 4 fragment
Int-4-r GCGGTACCTCGGAGAGGGAACTGTAATC
Int-4-s GCGGTACCTGGCTGAGTGATCAAACCGT Forward and reverse primers to make exon 5 fragment
Ex-5-r CGAAGCTTGGCGGCGCGTAAGGACAGG
IVS4+5G>C-f GAGTCCGGGTAGcAGCCAGCACGGAG Forward and reverse overlap PCR primers to make IVS4+5G>C mutant
IVS4+5G>C-r CTCCGTGCTGGCTgCTACCCGGACTC
IVS5-11A>G-f CTCCCTTGCCCCAgCCGCCCCCAGG Forward and reverse overlap PCR primers to make IVS5-11A>G mutant
IVS5-11A>G-f CCTGGGGGCGGcTGGGGCAAGGGAG
IVS4-1G>T-f CGTTTTCAtAGAAAGAT Forward and reverse overlap PCR primers to make IVS4-1G>T mutant
IVS4-1G>T-f ATCTTTCTaTGAAAACG
T7 promoter TAATACGACTCACTATAGGG Forward primer to pcDNA T7 promoter to detect minigene mRNA
PCREx-1b-f TGTCGGCCGTCTCCTCATCTTCC Forward and reverse primers to detect endogenous and minigene mRNA
PCREx-5-r TTGCGCTCCCTCTTTCTCCATTTG
GFP-f GACGGCAACATCCTGGGGCACAAG Forward and reverse primers to GFP
GFP-r CGGCGGCGGTCACGAACTCC
GAPDH-f TGATGACATCAAGAAGGTGGTGAAG Forward and reverse primers to GAPDH
GAPDH-r TCCTTGGAGGCCATGTGGGCCAT
*Primers are 5' to 3', mutations are in lowercaseBMC Medical Genetics 2006, 7:59 http://www.biomedcentral.com/1471-2350/7/59
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intron retention yields a ~386 nt band. The GFP probe
generates a ~309 nt protected band. Results were visual-
ized by autoradiography and quantitated with a Storm
820 PhosphorImager (Amersham Biosciences).
Western Blotting
HEK 293 cells were transfected with 2 μg p3X-FLAG mini-
gene DNA and 1 μg pEGFP as described. Cells were
washed with phosphate buffered saline, harvested by
scraping, the cells were resuspended in water, an equal
volume of 2× solubilizing buffer (2% SDS, 10% β-mer-
captoethanol, 5% glycerol, 50 μM Tris, pH 7, 0.005%
bromphenol blue) was added, and samples were soni-
cated for five seconds. Samples were subjected to 10%
SDS-PAGE and transferred to nitrocellulose membrane by
electrotransfer. Immunoblotting was done as described
[33], blots were blocked with nonfat dry milk, incubated
with anti-FLAG M2 monoclonal primary antibody
(Sigma) or anti-GFP monoclonal primary antibody (Cov-
ance), and after washing, goat anti-mouse IgMμ HRP-con-
jugate secondary antibody (Upstate) was applied. Blots
were developed using Supersignal West Pico Chemilumi-
nescent Substrate (Pierce). Results were visualized by
autoradiography or images were obtained using a
Fluorchem IS-8800 (Alpha Innotech).
Results
Identification of two new families with intronic PITX2 
mutations
DNA samples obtained from new patients with Axenfeld-
Rieger syndrome and anomaly were screened for muta-
tions in exons and at least 100-bp in the adjacent intron
regions. Two new families with intronic PITX2 mutations
have been identified. The first mutation was identified in
a patient (0175) affected with ARS (Figure 1A). The
patient displayed all classic features of this condition and
some additional defects: Rieger anomaly of the eye, wide-
spaced eyes, thin upper lip, hypoplastic maxilla, dental
defects, redundant periumbilical skin, and an anteriorly
placed anus. The mutation identified in this patient is a
G>T change in the -1 position of the 3' ss associated with
exon 4 (IVS4-1G>T) (g.18072G>T as seen in PITX2
sequence GenBank # AF238048; Figures 1A and 2C). Both
parents display a normal phenotype; testing of the
patient's mother confirmed normal PITX2 sequence (data
not shown) and the father was not available for testing.
This mutation was reported previously in an ARS patient
with severe ocular malformations, underdeveloped max-
illa and redundant umbilical skin [25]. Perveen et al. [18]
reported a G>C mutation at the same position and
affected individuals from this family demonstrated severe
ARS phenotypes: severe iris hypoplasia emulating aniridia
in one patient and joint hypermobility and an anteriorly
placed anus in another individual were reported.
Axenfeld-Rieger pedigrees with intronic mutations in PITX2 Figure 1
Axenfeld-Rieger pedigrees with intronic mutations in 
PITX2. A. Pedigree of family 0175 and sequence of genomic 
DNA of the patient showing an intronic mutation in the AG 
dinucleotide at the 3' ss splice junction of exon 4 (boxed). 
Proband is indicated with an arrow. B. Pedigree of family 689. 
Proband is indicated with an arrow. Individuals affected with 
an isolated ocular phenotype according to family history are 
indicated by half-shaded circles or boxes. Individuals affected 
with subclinical phenotypes who are likely mutation carriers 
are indicated with half-striped boxes. ARA, Axenfeld-Rieger 
anomaly. C. Pedigree of family 2 with clinical features. 
Proband is indicated with an arrow. Individuals affected with 
classic Axenfeld-Rieger syndrome (includes the triad of ocu-
lar, dental and umbilical anomalies) are indicated as shaded 
circles or boxes. ARS, Axenfeld-Rieger syndrome. The 
shaded triangle indicates a miscarriage of a child of unknown 
sex.
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The second mutation was found in patient 689, who dis-
played Axenfeld-Rieger anomaly in one eye only and no
craniofacial, dental or umbilical abnormalities. The
patient had normal ocular pressure and vision, the right
eye had a posterior embryotoxon visible on slit lamp
exam with iris sheets sweeping up to the embryotoxon
inferiorly, and no iris hypoplasia was noted. Slit lamp
exam of the left eye demonstrated normal development.
Clinical family history of this patient contains records of
developmental ocular defects but dental or umbilical
anomalies were never noted (Figure 1B). The mutation
was identified as a G>C substitution at the +5 position of
the 5' ss of PITX2 exon 4 (IVS4+5G>C)(g.18283G>C as
seen in PITX2 sequence GenBank # AF238048; Figures 1B
and 2C). The same change was previously reported in a
patient affected with the complete ARS [9]. Collection and
examination of clinical information from this family indi-
cated a substantial family history of complete ARS (pedi-
gree and clinical diagnoses are shown in Figure 1C).
Analysis of PITX2c RNA splicing using a minigene construct
Most Rieger syndrome patients have point mutations in
the coding region of PITX2 [9] and most of these affect the
DNA binding homeodomain [35]. Previous work and the
data above brings to eight the number of families with
mutations that do not affect the protein coding potential
of the gene, and the number of different mutations is now
five [9,17,18,21,25]. We set out to examine three recurrent
intronic mutations, each of which was described in two
unrelated families of Axenfeld-Rieger spectrum, and to
correlate the phenotypes with potential molecular defects
in pre-mRNA splicing. The IVS4-1G>T and IVS4+5G>C
mutations were described above. A third mutation studied
was an A>G change 11 nt upstream of the 3'ss of exon 5
(IVS5-11A>G) that was originally described in family 4 by
Semina et al. [9] and later by Borges et al. [21] who
reported the same change in another family (family 5);
both families displayed classic features of ARS.
The PITX2 gene is located at 4q25 and numerous isoforms
are produced through the use of alternative promoters
and extensive alternative splicing of the six exons (Figure
2A) [28]. PITX2 is expressed developmentally and in some
adult tissues but not blood (EVS, unpublished) and thus
patient samples to analyze splicing directly are not readily
available. To overcome this limitation, a minigene for
expression in tissue culture cells was designed that
included the exons that comprise one of the common
PITX2 isoforms, PITX2c, (Figure 2B) [36]. Since the signals
required for constitutive splicing are usually within ~100
PITX2 gene and minigene structure Figure 2
PITX2 gene and minigene structure. A. Schematic of PITX2 gene organization (drawn to scale). Open boxes represent 
exons, lines represent introns. The sizes of exons and introns are shown. The PITX2 gene has two major promoters (arrows) 
and six exons. Alternative splicing and transcription start sites give three major isoforms (not shown). PITX2c uses the down-
stream promoter and produces an mRNA containing exon 1b, 4, and 5. B. Schematic of PITX2c minigene. The minigene con-
tains a portion of exon 1b, exon 4, part of exon 5, and uses the CMV promoter and bGH polyadenylation site from the 
pcDNA3.1/myc-His(-)A vector (transcribed vector sequences are represented by shaded boxes). The lengths of intron regions 
associated with each exon are shown with vertical lines indicating the fusion of two fragments. The positions of the T7 primer 
to vector sequences, and primers to PITX2 exons 1b and 5 that were used for RT-PCR are shown below the diagram. C. 
Expansion of (B) showing the names and locations of three different intronic point mutations identified in ARS patients. The 
sequence surrounding the 5' and 3' splice sites of exon 4, and the 3' ss of exon 5 is shown. Mutations in patients 0175 (IVS4-
1G>T), 689 or 2 (IVS4+5G>C), and 4 (IVS5-11A>G) are indicated by arrows and the nucleotide changes are shown.
2661
3776 57 136
472
9307 778 206
886
2477
3537
1a 2 3 1b 4 5
130 244
1b 4 5
229 264
206
183 303
410 239
A
B
…cgttttcag gtaggagcc… AGAA……...……GG
IVS4-1G>T
3'ss 5'ss
IVS4+5G>C
…tcgtttgtctcccttgccccaaccgcccccag
IVS5-11A>G
3'ss
C GTTTG..
T7BMC Medical Genetics 2006, 7:59 http://www.biomedcentral.com/1471-2350/7/59
Page 6 of 13
(page number not for citation purposes)
nucleotides of splice junctions [32,37], the introns were
truncated to facilitate DNA cloning. Because there is no
evidence that the extensive 5' and 3' untranslated regions
are needed for constitutive splicing, exons 1b and 5 were
also truncated; exon 1b starts 40 nt upstream of the trans-
lation start codon and the exon 5 fragment ends with the
last amino acid codon. Minigene splicing was analyzed in
HeLa and HEK293 cells since they have been used exten-
sively to study constitutive RNA splicing. Additionally,
cornea stromal cells (generously provided by Dr. Watsky,
University of Tennessee) [38] were used since PITX2 is
expressed during corneal development and this cell line
endogenously expresses PITX2, and thus may more faith-
fully reproduce PITX2  splicing that occurs in patients.
HeLa and HEK293 cells were mock transfected or trans-
fected with 2 μg of minigene DNA and/or a GFP-express-
ing transfection control plasmid and RT-PCR was
performed on RNA isolated 40–48 h later. While PITX2c
is not expressed in these cell types (data not shown), to
ensure that only minigene RNA was detected, an upstream
primer complementary to vector sequence was used in
combination with a primer specific to PITX2 exon 5. Cor-
rect splicing would result in a 585 bp RT-PCR product
whereas unspliced RNA would produce a 1564 bp prod-
uct. The 585 bp band was observed only from transfected
HEK293 cells and analysis of GFP expression demon-
strated equivalent transfection efficiency and gel loading
(Figure 3A, lanes 2 and 3). Similar results were obtained
with HeLa cell RNA (data not shown). These results sug-
gest that the HeLa and HEK293 cells faithfully express cor-
rectly spliced minigene RNA. As an additional test to
verify the utility of the minigene, human cornea stromal
cells were similarly examined. The primer pair specific for
the minigene resulted in the 585 bp spliced product only
in transfected cells (Figure 3B, lanes 2 and 3, top) whereas
a primer pair that does not distinguish between trans-
fected and endogenous PITX2c mRNA produced a 404 bp
product that was present in both but more abundant in
transfected cells, consistent with correct splicing of endog-
enous and transfected PITX2 mRNA in corneal cells (lanes
2 and 3, middle). Analysis of cellular GAPDH showed
equal sample loading (Figure 3B, bottom).
To further assess the accuracy of minigene mRNA splicing
in HEK293 and human cornea stromal cells, the RT-PCR
products were cloned and three and four independent
clones were sequenced, respectively. Each sequence
showed correct minigene splicing (Figure 3C). These data
indicate that the PITX2c  minigene was efficiently and
accurately spliced and therefore validated the system for
determining the effects of patient mutations on RNA
splicing. This system would not address potential tissue-
specific splicing defects that may be important for ARS.
A G>T mutation at the 3' splice site of exon 4 shifts splicing 
2 nt downstream
Patient 0175 reported here and patient 2 previously
described by Lines et al. [25] display severe features of ARS
(see above) and harbor a G>T mutation in the -1 position
of the 3' ss of exon 4 mutation (IVS4-1G>T) (Figures 1A
and 2C). This changes the canonical "AG" acceptor splice
site to an "AT". In addition, a G>C substitution at the
same site was previously reported in a patient that dis-
played classic ARS [18,25]. To test the effect of the G>T
mutation on splicing, the three cell lines were transfected
with WT or IVS4-1G>T minigenes and the splicing status
of the mRNA was analyzed by RT-PCR. A single RT-PCR
product of the appropriate size for correctly spliced RNA
was observed with HEK293 (Figure 4A, top, lane 3), cor-
nea stromal (bottom, lane 7), and HeLa cell RNA (not
shown). A GFP-expressing plasmid used as a transfection
and RNA loading control showed equal loading in each
case (Figure 4A). To examine the possibility that a subtle
change in splicing occurred that was not obvious from the
size of the RT-PCR product, the PCR products were cloned
and 13 HEK293 and three cornea cell independent clones
were sequenced. All sequences showed that splicing was
shifted 2 nt downstream to the next available "AG" dinu-
cleotide (Figure 4B). Based on the results with the mini-
gene in cultured cells, it is likely that all PITX2 mRNA
from this allele is incorrectly spliced in these patients.
A G>C mutation 5 nt downstream of the 5' splice site of 
exon 4 results predominantly in intron retention
The G>C mutation at the +5 position of the 5'ss of exon 4,
IVS4+5G>C, was originally described in a family with ARS
[9] and above we described the same mutation in a
patient 689 with an isolated Axenfeld-Rieger anomaly. To
assess the effect of this mutation on splicing, HeLa,
HEK293, and human cornea stromal cells were trans-
fected with wild type (WT) or mutant minigenes and GFP,
and the isolated RNA was analyzed by RT-PCR. As shown
in Figure 5A for HEK293 and cornea stromal cells, a band
of the size expected for correctly spliced RNA was again
observed from the WT minigene (lanes 2 and 5) but two
RT-PCR products were seen with IVS4+5G>C (lanes 3 and
6). The lower band size was consistent with correctly
spliced minigene RNA whereas the second product was
larger but not the expected size for completely unspliced
RNA. Analysis of GFP showed equal loading for each sam-
ple (Figure 5A). Similar results were seen with HeLa cell
RNA (data not shown).
To determine the nature of the aberrant PCR product
observed from the IVS4+5G>C minigene, both RT-PCR
products from HEK293 RNA were cloned and independ-
ent clones of six large products and eleven 585 bp prod-
ucts were sequenced. The sequences showed that the
lower band of IVS4+5G>C RNA was derived from cor-BMC Medical Genetics 2006, 7:59 http://www.biomedcentral.com/1471-2350/7/59
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rectly spliced mRNA and that the upper band retained the
intron between exons 4 and 5 (Figure 5B).
To accurately quantitate the frequency of intron retention
in IVS4+5G>C RNA, an RNase protection assay (RPA) was
performed using a 700-nt riboprobe that spanned the 206
nt exon 4 and included upstream and downstream intron
sequences. Correctly spliced RNA results in a ~206 nt pro-
tected band while retention of the intron would yield a
386 nt band (Figure 5C). RNA from the WT minigene was
virtually completely spliced (Figure 5D, lane 4) whereas
approximately 71% of the RNA from IVS4+5G>C retained
the second intron (Figure 5D, lane 5). Thus, mutation
IVS4+5G>C causes significant disruption in PITX2c mini-
gene splicing.
An A>G mutation 11 nt upstream of the 3' splice site of 
exon 5 shifts splicing to that site
The previously reported patients from family 4 [9] and
family 5 [21] have classic ARS and harbor an A>G muta-
tion 11 nt upstream of the 3' ss associated with PITX2
exon 5 (mutation IVS5-11A>G) (g.20745A>G as seen in
PITX2  sequence GenBank # AF238048; Figure 2C). To
determine if this mutation affects splicing, HeLa, HEK293
and human cornea stromal cells were transfected with the
WT or IVS5-11A>G minigenes and the isolated RNA was
The PITX2c minigene is expressed and the mRNA splices normally Figure 3
The PITX2c minigene is expressed and the mRNA splices normally. A. HEK293 cells were transfected with a GFP 
transfection control plasmid with (+) or without (-) 2 μg of the minigene. Transfected-cell RNA was isolated and subjected to 
RT-PCR with primers to the minigene (top) or GFP (bottom) and the products were resolved on an agarose gel. The position 
of correctly spliced product for the minigene and GFP is shown at the right. M, 100 bp size standards with selected sizes 
shown. B. Human cornea stromal cells were either mock transfected (-) or transfected with 2 μg of minigene DNA (+). RNA 
was isolated and analyzed by RT-PCR with primers that amplify only minigene mRNA (top) or those that amplify both minigene 
and endogenous PITX2c mRNA (middle), or to cellular GAPDH (bottom), and products were resolved on an agarose gel. Prim-
ers are depicted in Figure 2B. M, 100 bp size standards with selected sizes shown. The positions of correctly spliced products 
are shown at the right. C. Sequence of spliced products. RT-PCR products were cloned and sequenced. At the top is a sche-
matic of the pre-mRNA with exon sequences boxed and in uppercase and intron sequences in lowercase. Lines extend from 
splice sites to the spliced product sequence shown at the bottom.
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analyzed by RT-PCR. The RT-PCR product from IVS5-
11A>G RNA was the same size as correctly spliced PITX2c
mRNA (Figure 4A, lanes 4 and 8). PCR of GFP served as a
loading control. To determine if the mutation caused an
aberrant splice that did not alter the RT-PCR product size
appreciably, the RT-PCR product was cloned and 11 inde-
pendent HEK293 clones were sequenced. All of the
sequences showed that splicing was shifted exclusively to
the newly created "AG" dinucleotide acceptor site 11 nt
upstream of the authentic 3' ss (Figure 4C). Based on these
results, it is likely that PITX2 mRNA from this allele is
always incorrectly spliced in these patients.
Analysis of PITX2c protein expression
Aberrantly spliced mRNA derived from the mutant patient
PITX2 genes is expected to result in truncated PITX2c pro-
tein since frameshifts occur in each case (Figure 6A).
PITX2 protein levels were determined in transfected cells
by western blot (Figure 6B) after normalizing protein lev-
els to GFP expression and RNA expression as determined
by RPA. RPA analysis demonstrated that mRNA expres-
sion was roughly similar for each minigene (Figure 6C)
and that, except for IVS4+5G>C, each minigene mRNA
was doubly spliced (although aberrantly).
The WT minigene produced a protein of the expected size,
~36 kDa (Figure 6B, lane 1). The IVS4-1G>T minigene
produced a much smaller protein (~12 kDa, lane 4), but
this was expected since this protein would terminate at a
single frame-shifted amino acid after PITX2 position 70. It
appears that the IVS4-1G>T protein is unstable since it
was present at only ~5% of WT levels, despite its mRNA
being at least as abundant as WT. The IVS4+5G>C mRNA
generated a normal sized protein and a second product of
the size (~29 kDa) appropriate for truncated protein
derived from intron-containing mRNA (lane 2); when
corrected for mRNA levels, the truncated protein was
about one tenth the abundance of normal protein. It was
also evident that the level of normal protein expressed
from the IVS4+5G>C minigene was roughly proportional
to correctly spliced mRNA levels, which was about 30% of
that produced from the WT minigene. Conversely, the
level of truncated protein generated from the intron-
retaining mRNA (~71% of minigene RNA produced) was
considerably less than expected if protein expression was
proportional to mRNA. These data are consistent with
inefficient export of the intron-containing IVS4+5G>C
mRNA from the nucleus. However, the possibility that the
mRNA is exported but not translated, or exported but pro-
duces an unstable protein, cannot be excluded. Finally,
the IVS5-11A>G mRNA would direct synthesis of a pro-
tein containing 138 residues of PITX2 followed by 117
frame-shifted amino acids and again, an expected ~33
kDa protein was expressed (lane 3) at a level similar to
WT.
Mutants IVS4A-1T and IVS5-11A>G splice aberrantly Figure 4
Mutants IVS4A-1T and IVS5-11A>G splice aber-
rantly. A. Analysis of transfected-cell RNA by RT-PCR. RNA 
from HEK293 cells (lanes 2–4) or human cornea stromal 
cells (lanes 6–8) transfected with GFP and the indicated mini-
gene was analyzed by RT-PCR and products were resolved 
on an agarose gel. The position of correctly spliced minigene 
product (585 bp) and GFP is shown at the right. M, 100 bp 
size standards with selected sizes shown. WT, RNA from 
wild type minigene; -1G>T, RNA from mutant IVS4-1G>T 
minigene; -11A>G, RNA from mutant IVS5-11A>G minigene. 
B. Schematic of the 3'ss used in the IVS4-1G>T RT-PCR 
products from (A) that were cloned and sequenced. C. Sche-
matic of the RNA sequence of patient IVS5-11A>G RT-PCR 
products from (A) that were cloned and sequenced. In B and 
C, exon sequences are boxed and in uppercase, intron 
sequences are in lowercase, and an arrow points to the 
patient mutation.
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The IVS4+5G>C mutation causes intron retention Figure 5
The IVS4+5G>C mutation causes intron retention. A. RNA from HEK293 cells (lanes 2 and 3) or human cornea stro-
mal cells (lanes 5 and 6) transfected with WT or IVS4+5G>C minigenes and GFP was subjected to RT-PCR and products were 
resolved on an agarose gel. The positions of correctly spliced (585 bp), intron retention (1071 bp), and GFP products are 
shown at the right. M, 100 bp size standards with selected sizes shown. B. Diagram depicting the RNA structure of RT-PCR 
products from (A) that were cloned and sequenced. At the top is correctly spliced RNA, the bottom is RNA that retains the 
intron downstream of exon 4. C. Schematic of the RNase protection probe and protected products observed in D. The sizes 
of the probe and protected products are indicated. D. RNase protection assay (RPA). HEK293 RNA was subjected to RPA, 
protected products were resolved on a 6%–8 M urea polyacrylamide gel, and a phosphorimage is presented. Correct splicing 
generates a ~206 nt band and intron retention gives a ~386 nt band. M, 32P-labeled pBR322/MspI markers with sizes indicate 
on the left; P, undigested probe; mock, RPA using RNA from untransfected cells; WT, RNA from WT minigene-transfected 
cells; +5G>C, RNA from mutant IVS4+5G>C minigene-transfected cells. The positions of correctly spliced and intron reten-
tion protected products are shown at the right. The doublet bands for spliced product are likely due to incomplete RNase 
digestion. Below the lanes is quantitation of % intron retention (+/- standard deviation) as assessed by PhosphorImager analysis 
(n = 17).
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Discussion
We report two new families with intronic mutations in the
PITX2  gene and give insights into the mechanisms by
which these and a previously described intronic mutation
may affect PITX2 protein expression and influence devel-
opment of ARS. A deficiency in normal PITX2 protein was
proposed as the major cause of ARS and each of the muta-
tions examined caused RNA splicing defects that would
affect PITX2 protein levels or function, consistent with a
gene dosage model for development of the syndrome.
Mutation IVS4-1G>T is the most 5' positioned PITX2
mutation identified to date ([18], [25], this report). This
mutation changes the 3' intron-terminal G to a T and
mutates the terminal "AG" intron junction dinucleotide.
The terminal AG dinucleotide is critical for splicing catal-
ysis and it was expected that splicing at the correct site
would be abolished. A number of mechanisms for speci-
fying the 3' ss AG have been proposed, including scanning
from the branchpoint to the first AG [39], measurement
from the branchpoint to the AG [40], or a combination of
the AG being in the correct context and an optimal dis-
tance from the branchpoint [41]. The next available AG
was located immediately 3' to the mutated junction and
splicing was completely shifted to this site. Because of
aberrant splicing, the resulting protein is predicted to con-
tain only the N-terminal 70 amino acids of PITX2 and lack
the entire homeodomain and C-terminal region. Extrapo-
Analysis of protein expression from mutant minigenes Figure 6
Analysis of protein expression from mutant minigenes. A. The domain structure of PITX2c protein with the position 
of the homeodomain (HD) is shown. Lines below represent the proteins that would result from aberrantly spliced RNA 
caused by each of the mutations. Straight lines indicate normal protein and jagged lines indicate incorrect amino acids gener-
ated by frame shifts; the number of normal amino acids and full-length size is shown for each. B. Western blotting of indicated 
FLAG epitope-tagged PITX2c and GFP proteins expressed in HEK293 cells. WT, protein from a wild type minigene transfec-
tion; +5G>C, protein from IVS4+5G>C mutant minigene transfected cells; -11A>G, protein from IVS5-11A>G mutant mini-
gene transfection; -1G>T, protein from IVS5-11A>G mutant minigene transfected cells. The positions of wild type, +5G>C, -
11A>G, and -1G>T PITX2 protein, and GFP protein, are indicated at the right. C. RNase protection assay (RPA). RNA from 
the indicated transfections was subjected to RPA with the same probe used in Figure 5, protected products were resolved on 
a 6%–8 M urea polyacrylamide gel, and a phosphorimage was obtained. Correct PITX2c splicing generates a ~206 nt band and 
GFP generates a 309 nt band. M, 32P-labeled pBR322/MspI markers with sizes indicated on the left; P, undigested probes; mock, 
RNA from GFP-transfected cells. The positions of correctly spliced and GFP protected products are shown at the right. The 
asterisks denote artifact bands derived from the GFP probe. The multiple bands for spliced product are likely due to incom-
plete RNase digestion. Below the lanes is quantitation of splicing relative to WT as assessed by PhosphorImager analysis.
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lation of our analysis in tissue culture cells to the patient
suggests that the mutant protein would be present at neg-
ligible amounts and therefore, the patient's phenotype is
most easily explained by haploinsufficiency of wild-type
PITX2 protein (50% of normal). Interestingly, two unre-
lated patients with mutations at this nucleotide manifest
ARS with one extra feature not commonly reported in ARS
pedigrees – an anteriorly placed anus (this report; [18]).
Also, two previously reported families with IVS4-1G>T
and -1G>C substitutions were noted to display a severe
form of Axenfeld-Rieger ocular anomaly including ani-
ridia (unfortunately, detailed records were not available
for patient 0175 reported here). Whether these features
might be truly associated with this type of mutation and
are caused by expression of only the N-terminal end of
PITX2 remains to be seen.
The second mutation studied was identified in an individ-
ual (689) from a family with Axenfeld-Rieger anomaly
and normal dental and umbilical development. The
mutation is a change at position +5 of the 5'ss at the
downstream border of exon 4 that led to predominant
intron retention. This was surprising since exon skipping
was the expected outcome. It is possible that our mini-
gene/transfection system does not reflect the outcome in
patients, but splice site mutations do result in intron
retention at reasonable frequencies [42]. Curiously, the
same mutation was previously reported in a family
affected with complete ARS [9]. Little protein was gener-
ated from the aberrant mRNA and that which is made
would be nonfunctional since it is truncated in the home-
odomain. Since expression of the mutant allele in trans-
fected cells resulted in 30% correctly spliced mRNA, the
patient might be expected to have a milder phenotype
since PITX2 protein would be ~65% of normal rather than
the 50% expected of haploinsufficiency.
While our study demonstrates that the IVS4+5G>C muta-
tion causes a similar level of intron retention in three tis-
sue culture cell systems, it is curious that two individuals
with the same mutation (families 689 and 2) exhibited
different phenotypes and have corresponding clinical
family histories (Figures 1B and 1C)[9]. Unfortunately,
patient samples cannot be examined directly, but it is pos-
sible that the degree of aberrant splicing differs in these
individuals, with a greater amount of aberrant splicing
associated with a more severe phenotype. The mutation
should alter recognition of the 5'ss by the core splicing
machine, an event that is influenced by numerous posi-
tive and negative auxiliary factors whose expression pat-
terns often show cell-type specific and temporal variation
[32]. For example, trans-acting splicing activators often
promote recognition of exons and correct splicing
through interactions with splicing enhancer sequences
located in exons. Indeed, purine-rich sequences upstream
of the affected PITX2 5'ss resemble splicing enhancer ele-
ments that bind the SR protein family of splicing activa-
tors [43]. It is possible that genetic background differences
influence the levels of one or more of these factors, result-
ing in differential effects of the IVS4+5G>C mutation on
splicing in the two patients. The mutation would manifest
as a less severe splicing defect, and thus higher levels of
wild-type protein in the patient with the milder pheno-
type. It is also possible that the putative splicing enhancer
elements in exon 4 explain the intron retention outcome
by promoting recognition of the exon such that splicing of
the upstream intron occurs, but the mutation in the 5' ss
abolishes downstream intron splicing. Another possibility
is genetic variation in the promoters of PITX2 target genes
such that lower levels of PITX2 protein activate them.
The IVS4+5G>C PITX2 mutation represents another dem-
onstration of affected phenotypes associated with a more
than 50% level of normal PITX2 protein. In previous
reports, it was argued that some of the PITX2 mutant pro-
teins retain partial function and this fact explains milder
ARS phenotypes seen in affected families [19,31]. Another
observation emerging from these studies is that human
ocular development appears to be the most sensitive to
the amounts of PITX2 protein as "mild" mutations allow
dental and umbilical development to proceed normally
but still have a profound effect on ocular structures, while
"severe" mutations result in more complex ocular defects
(this report; [19,20,30,31]).
The third mutation (IVS5-11A>G) reported in two fami-
lies with classic ARS is an A>G mutation located eleven
nucleotides upstream of the 3' ss associated with exon 5
[9,21]. An important determinant of 3'ss strength is the
polypyrimidine tract that lies between the branch point
and the splice junction [32]; purine interruptions decrease
3'ss quality. The IVS5-11A>G mutation would not be
expected to alter the strength of the 3' ss but the mutation
does create a new "AG" dinucleotide and that could com-
pete with the authentic one 11 nt downstream. As dis-
cussed above, this new AG could be recognized by
scanning due to the fact that a pyrimidine tract is located
upstream or by a mechanism similar to that described in
Coffin-Lowry syndrome whereby the authentic AG in the
RSK2 gene is involved in the first steps of splicing but the
new AG is utilized in the second step as the splice junction
[44]. Regardless, a complete shift in IVS5-11A>G mini-
gene RNA splicing to the new site was observed and
resulted in expression of a truncated protein that lacks a
functional homeodomain. ARS phenotype in these fami-
lies included classic ocular, dental and umbilical features
(this report; Dr. Nishimura, personal communication)
and can be explained by haploinsufficiency although the
possibility that the mutant protein provides an additional
effect cannot be excluded.BMC Medical Genetics 2006, 7:59 http://www.biomedcentral.com/1471-2350/7/59
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Conclusion
In summary, we provide the first direct evidence that
PITX2 intronic mutations cause splicing defects. We pro-
pose that the molecular defect in patients harboring these
mutations is at the level of mRNA splicing such that the
level of functional protein is reduced. Furthermore, the
extent of the splicing defect observed in our system gener-
ally correlates with phenotypic severity, which supports
the PITX2  gene dosage model for Axenfeld-Rieger syn-
drome. Because the mutations described here affect splic-
ing of the last two exons that are common to all isoforms,
similar splicing defects would be expected for all PITX2
transcripts. The gene dosage model was initially proposed
based on in vitro studies that demonstrated an association
between partial function for some mutant PITX2 proteins
and milder phenotypes. Here, we report a splicing muta-
tion (IVS4+5G>C) that results in production of some nor-
mal mRNA/protein from a minigene, which suggests an
association between elevated levels of normal PITX2
(~65% vs. 50%) and milder human phenotypes. We also
suggest that the phenotypic outcome may be dependent
on secondary factors/genetic background of mutation car-
riers.
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